RESEARCH TRIANGLE PARK, N.C , Oct. 22, 2024 /PRNewswire/ -- Dignify Therapeutics (Dignify), a leading developer of therapies for bladder and bowel dysfunction, has been selected as a participating company in the Praxis Spinal Cord Injury (SCI) Accelerate Program.
SCI Accelerate is a commercialization program 'geared towards healthcare companies with a product ready to launch into market that will transform the lives of people living with SCI'. Under the SCI Accelerate program, Dignify and Praxis will focus on development of Dignify's drug programs to treat bladder and bowel disorders in people with SCI. Dr.
Karl B. Thor , Chief Scientific Officer of Dignify, indicated; "The Praxis SCI Accelerate Program is critically important for Dignify to ensure that the clinical development program for our products provides the efficacy, safety, and convenience that are considered valuable and most important by SCI individuals for control of bowel and bladder dysfunction. The selection of Dignify to join the Praxis SCI community confirms the unmet medical need for our therapeutics.
" Arushi Raina , Praxis Director of Commercialization, stated "The Praxis team was impressed by the Dignify team's approach and excited by the possibility of a bowel and bladder treatment that could be used in an accessible way to transform daily living." About Dignify Therapeutics Founded by a team of serial entrepreneurs who are internationally recognized scientists and clinicians, Dignify's mission is to prov.